Biotech Values

[DewDiligence]

QURE—…the hemophilia B gene therapy could be a game changer as it offers the potential to eliminate the need for routine Factor IX replacement.

The first time I read about the concept of gene therapy many years ago, the application being discussed was hemophilia. It’s been a long time coming.

From a business standpoint, is there a bona fide need for a (presumably very expensive) gene therapy for hemophilia B now that there are multiple long-acting FIX products on the market or nearing commercialization?